Healthcare Services

Rising diabetes prevalence is boosting the endocrine testing market

April 21, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Large Will The Endocrine Testing Market Be By 2030 Compared To Its 2026 Market Size?

The endocrine testing market size has experienced robust growth in recent years. Projections indicate a rise in market value from $2.79 billion in 2025 to $3.05 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.4%. Factors contributing to this historical expansion include the increasing prevalence of diabetes, higher incidence of thyroid disorders, the expansion of clinical laboratories, enhanced awareness of hormone testing, and the broader growth in chronic disease diagnostics.

The endocrine testing market is projected to experience robust expansion in the coming years. This market is anticipated to reach $4.15 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.9%. This projected growth during the forecast period is driven by factors such as a greater emphasis on preventive healthcare, personalized treatment strategies, automation within hormone testing procedures, the increase in diagnostic center facilities, and the implementation of endocrine disease screening initiatives. Key trends anticipated for the forecast period encompass an increasing incidence of hormonal disorders, a wider uptake of extensive hormone panels, the broadening scope of preventive endocrine screening, a heightened need for precise diagnostic outcomes, and the incorporation of sophisticated diagnostic technologies.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/endocrine-testing-global-market-report

What Leading Drivers Are Supporting The Endocrine Testing Market Expansion?

The escalating incidence of diabetes is projected to fuel the expansion of the endocrine testing market in the future. Diabetes encompasses a range of conditions characterized by elevated blood glucose levels. Its increasing occurrence is attributed to elements like poor dietary habits, inactive lifestyles, inherited susceptibilities, and an aging demographic. Endocrine assessments, such as hemoglobin A1c, fasting plasma glucose, and C-peptide examinations, are employed for diabetes management to identify the condition, track glucose concentrations, and evaluate insulin secretion and responsiveness. For example, data from June 2024, released by the National Health Service (NHS), a UK-based government department, shows a rise in cases among individuals under 40, increasing from 173,166 in 2022 to 216,440 in 2023. This notable increase underscores a troubling pattern within this particular age bracket. The figures demonstrate a swift upward trajectory in the occurrence of diabetes within younger demographics. Consequently, the growing prevalence of diabetes is serving as a primary impetus for the endocrine testing market.

How Are Segments Identified Within The Endocrine Testing Market Segment Framework?

The endocrine testing market covered in this report is segmented –

1) By Test Type: Estradiol (E2) Test, Follicle Stimulating Hormone (FSH) Test, Human Chorionic Gonadotropin (hCG) Hormone Test, Luteinizing Hormone (LH) Test, Dehydroepiandrosterone Sulfate (DHEAS) Test, Progesterone Test, Testosterone Test, Thyroid Stimulating Hormone (TSH) Test, Prolactin Test, Other Types

2) By Technology: Tandem Mass Spectrometry, Immunoassay, Monoclonal And Polyclonal Antibody Technologies, Sensor Technology, Clinical Chemistry, Other Technologies

3) By End-User: Hospitals, Clinical Laboratories, Diagnostic Centers, Other End-Users

Subsegments:

1) By Estradiol (E2) Test: Serum Estradiol Test, Urinary Estradiol Test

2) By Follicle Stimulating Hormone (FSH) Test: FSH Serum Test, FSH Urine Test

3) By Human Chorionic Gonadotropin (hCG) Hormone Test: Quantitative hCG Test, Qualitative hCG Test

4) By Luteinizing Hormone (LH) Test: LH Serum Test, LH Urine Test

5) By Dehydroepiandrosterone Sulfate (DHEAS) Test: Serum DHEAS Test, Saliva DHEAS Test

6) By Progesterone Test: Serum Progesterone Test, Urinary Progesterone Test

7) By Testosterone Test: Free Testosterone Test, Total Testosterone Test

8) By Thyroid Stimulating Hormone (TSH) Test: TSH Serum Test, TSH Saliva Test

9) By Prolactin Test: Serum Prolactin Test, Plasma Prolactin Test

10) By Other Types: Cortisol Test, Insulin Test, Growth Hormone (GH) Test, Aldosterone Test

What Emerging Trends Are Seen In The Endocrine Testing Market?

Major companies operating within the endocrine testing market are developing point-of-care testing solutions to enhance the accessibility and efficiency of diagnosing endocrine disorders. Point-of-care testing yields quick results, which can aid in the rapid diagnosis and management of heart failure in patients presenting with symptoms such as shortness of breath and fatigue. For instance, in April 2024, Roche Holding AG, a Switzerland-based pharmaceutical company, launched a point-of-care NT-proBNP test in India, specifically designed for screening diabetes patients at risk of cardiovascular diseases, such as heart failure (HF). This test facilitates early detection and intervention, enabling clinicians to identify high-risk T2D patients and initiate timely treatment discussions, ultimately fostering improved outcomes and patient well-being.

Who Are The Companies Competing Within The Endocrine Testing Market?

Major companies operating in the endocrine testing market are Thermo Fisher Scientific Inc., Abbott Laboratories, Roche Holding, Siemens Healthineers, Quest Diagnostics, Agilent Technologies Inc., PerkinElmer Inc., BioMérieux SA, Beckman Coulter Inc., Bio-Rad Laboratories Inc., SD Biosensor Inc., Qiagen N.V., Ortho Clinical Diagnostics, Kronus Inc., Randox Laboratories Ltd., Fujirebio Diagnostics Inc., Inova Diagnostics Inc., Sekisui Diagnostics LLC, Mercodia AB, ZEUS Scientific Inc., IBL International, Monobind Inc., Agilus Diagnostics, Tosoh Bioscience Inc., DiaSorin S.p.A.

Get The Full Endocrine Testing Market Report:

https://www.thebusinessresearchcompany.com/report/endocrine-testing-global-market-report

Which Region Is The Top Contributor To The Endocrine Testing Market By Share?

North America was the largest region in the endocrine testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the endocrine testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Endocrine Testing Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/endocrine-testing-global-market-report

Browse Through More Reports Similar to the Global Endocrine Testing Market 2026, By The Business Research Company

Thyroid Function Test Market Report 2026

https://www.thebusinessresearchcompany.com/report/thyroid-function-test-global-market-report

Endocrine Peptide Test Market Report 2026

https://www.thebusinessresearchcompany.com/report/endocrine-peptide-test-global-market-report

Hormone Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/hormone-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795